The interaction of selected phytochemicals, HIV drugs, and commercial-source herbal teas and capsules with human cytochrome P450 3A4 and P-glycoprotein

Pharmaceutical Biology

Volumn 46, Issue 1-2, 2008, Pages 53-65

  Budzinski, Jason W ^a   Foster, Brian C ^a,b   Trudeau, Vance L ^a   Drouin, Cathy E ^a   Bafi Yeboa, Nana ^a   Arnason, J Thor ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

CAM; CYP3A4; Drug interactions; Herbal extract; HIV; Inhibition; Natural health product; P glycoprotein; P gp ATPase; Tea

Indexed keywords

CYTOCHROME P450 3A4; ECHINACEA ANGUSTIFLORA EXTRACT; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; GINSENG EXTRACT; GLYCOPROTEIN P; HYDRASTIS CANDENSIS EXTRACT; HYPERICUM PERFORATUM EXTRACT; PLANT EXTRACT; SILYBUM MARIANUM EXTRACT; UNCARIA TOMENTOSA EXTRACT; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DRUG DISPOSITION; DRUG FORMULATION; DRUG INHIBITION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; PHYTOCHEMISTRY; TEA;

HYDRASTIS CANADENSIS; SILYBUM MARIANUM;

EID: 38849196790     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880200701729844     Document Type: Article

References (43)

1. Abourashed EA, Khan IA (2001): High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J Pharm Sci Technol 90: 817-822.
2. Ameer B, Weintraub RA (1997): Drug interactions with grapefruit juice. Clin Pharmacokinet 33: 103-121.
3. Awad R, Arnason JT, Trudeau V, Bergeron C, Budzinski JW, Foster BC, Merali Z (2003): Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): A medicinal plant with anxiolytic properties. Phytomedicine 10: 640-649.
4. Bernard CB, Krishnamurty HG, Chauret D, Sanchez PE, San Roman L, Poveda LJ, Hasbrun C (1995): Insecticidal Piperaceae of the neotropics. J Chem Ecol 21: 801-814.
5. Budzinski JW, Foster BC, Trudeau VL, Drouin CE, Panahi M, Arnason JT (2007): Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco2 cell monolayers by selected commercial-source milk thistle (Silybummarianum) and goldenseal (Hydrastis canadensis) products. Can J Physiol Pharmacol 85(9): 966-978.
6. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT (2000): An in vitro analysis of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7: 273-282.
7. Büter B, Orlacchio C, Soldati, A, Berger K (1998): Significance of genetic and environmental aspects in the field cultivation of Hypericum perforatum. Planta Med 64: 431-437.
8. CATIE (Canadian AIDS Treatment Information Exchange) (2005): A Practical Guide to Herbal Therapies for People Living with HIV. Toronto, CATIE.
9. Chatterjee P, Franklin MR (2003): Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31: 1391-1397.
10. Crespi CL, Miller VP, Penman BW (1997): Microtitre plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248: 188-190.
11. Cummins CL, Jacobsen W, Benet LZ (2002): Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300: 1036-1045.
12. Cummins CL, Mangravite LM, Benet LZ (2001): Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected caco2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res 18: 1102-1109.
13. Dasgupta A, Okhuysen PC (2001): Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 23: 591-605.
14. Duggan J, Peterson WS, Schultz M, Khuder S, Charkraborty J (2001): Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDs 15: 159-167.
15. Flora K, Hahn M., Rosen H, Benner, K (1998): Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93: 139-143.
16. Foster BC, Arnason JT, Briggs CJ (2005): Natural health products and drug disposition. Annu Rev Pharmacol Toxicol 45: 203-226.
17. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S (2001): An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4: 176-184.
18. Foster BC, Sockovie ER, Vandenhoek S, Bellefeuille N, Drouin CE, Krantis A, Budzinski JW, Livesey J, Arnason JT (2004): In vitro activity of St. John's wort against cytochrome P450 isozymes and p-glycoprotein. Pharm Biol 42: 159-169.
19. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT (2003): In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10: 334-342.
20. Foster BC, Vandenhoek S, Li KY, Tang R, Budzinski JW, Krantis A (2002): Effect of several Chinese natural health products on human cytochrome P450 metabolism. J Pharm Pharm Sci 5: 185-189.
21. GENTEST (1998a): Methodology of a High Throughput Method for Measuring Cytochrome P450 Inhibition (Version 2). GENTEST Technical Bulletin, Woburn, MA, GENTEST Corporation.
22. GENTEST (1998b): Human P-Glycoprotein (Pgp or MDR1) Membranes. GENTEST Technical Bulletin, Woburn, MA, GENTEST Corporation.
23. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Kahn IA, Edwards DJ, Shah A (2004): In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76: 428-440.
24. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Kahn IA, Shah A (2005): In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77: 415-426.
25. Harborne JB, Baxter H, Moss GP (1999): Phytochemical Dictionary (A Handbook of Bioactive Compounds from Plants, 2nd Edition). London, Taylor & Francis Ltd.
26. Kivistö KT, Niemi M, Fromm MF (2004): Functional interaction of intestinal CYP3A4 and p-glycoprotein. Fundam Clin Pharmacol 18: 621-626.
27. Lee LS, Andrade ASA, Flexner C (2006): Interactions between natural health products and antiretroviral drugs: Pharmacokinetic and pharmacodynamic effects. Clin Infect Dis 43: 1052-1059.
28. Maitrejean M, Comte G, Barron D, El Kirat K, Conseil G, Di Pietro A (2000): The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 10: 157-160.
29. McKnight I, Scott M (1996): Managing HIV part 7: Professional issues. 7.4: HIV and complementary medicine. Med J Aust 165: 143-145.
30. Mills E, Montori V, Perri, D, Phillips E, Koren G (2005): Natural health product-HIV drug interactions: A systematic review. Int J STD AIDS 16: 181-186.
31. Mouly SJ, Paine MF, Watkins PB (2004): Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 308: 941-948.
32. Nair VD, Foster BC, Arnason JT, Mills EJ, Kanfer I (2007): In vitro evaluation of human cytochrome P450 and P-glycoprotein-mediated metabolism of some phytochemicals in extracts and formulations of African potato. Phytomedicine 14(7-8): 498-507.
33. NSF International Institute for Nutraceutical Advancement (2004): Determination of Flavonol Derivatives (Silymarin Group) in Milk Thistle Fruit and Powdered Extract (Silymarins in Milk Thistle by HPLC - INA Method 115.000). Available at http://www.nsf.org/business/ina/milkthistle.asp.
34. Parasrampuria DA, Lantz MV, Benet LZ (2001): A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. Pharm Res 18: 39-44.
35. Piscitelli SC, Burstein AH, Welden N, Gallicano K, Falloon J (2002a): The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34: 234-238.
36. Piscitelli SC, Formentini RNC, Burstein AH, Alfaro R, Jagannatha S, Falloon J (2002b): Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22: 551-556.
37. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS (2001): Rational use of in vitro P-glycoprotein assays in drug discovery. Pharmacol Exp Ther 299: 620-628.
38. Scott IM, Leduc RI, Burt AJ, Marles RJ, Arnason JT, Foster BC (2006): The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals. Pharm Biol 44: 315-327.
39. Southwell IA, Bourke CA (2001): Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's wort). Phytochemistry 56: 437-441.
40. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K (2000): Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 97: 1433-1437.
41. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC (2000): Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyltransferase in human hepatocyte cultures. Drug Metab Dispos 28: 1270-1273.
42. Zeng X, Zeng X (1999): Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC. Biomed Chromatogr 13: 442-444.
43. Zühlsdorf MT (1998): Relevance of pheno- and genotyping in clinical drug development. Int J Clin Pharmacol Ther 36: 607-612.